156 related articles for article (PubMed ID: 38548067)
21. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.
; ; ;
Diabetologia; 2024 Jun; ():. PubMed ID: 38869512
[TBL] [Abstract][Full Text] [Related]
22. Noninvasive identification of probable fibrotic nonalcoholic steatohepatitis across the spectrum of glucose tolerance in the United States.
Ciardullo S; Carbone M; Invernizzi P; Perseghin G
Diabetes Res Clin Pract; 2023 May; 199():110679. PubMed ID: 37094749
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis.
Ravaioli F; Dajti E; Mantovani A; Newsome PN; Targher G; Colecchia A
Gut; 2023 Jul; 72(7):1399-1409. PubMed ID: 36599683
[TBL] [Abstract][Full Text] [Related]
24. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.
Ajmera V; Cepin S; Tesfai K; Hofflich H; Cadman K; Lopez S; Madamba E; Bettencourt R; Richards L; Behling C; Sirlin CB; Loomba R
J Hepatol; 2023 Mar; 78(3):471-478. PubMed ID: 36410554
[TBL] [Abstract][Full Text] [Related]
25. MEFIB-Index and MAST-Score in the assessment of hepatic decompensation in metabolic dysfunction-associated steatosis liver disease-Individual participant data meta-analyses.
Noureddin N; Ajmera V; Bergstrom J; Bettencourt R; Huang DQ; Siddiqi H; Majzoub AM; Nayfeh T; Tamaki N; Izumi N; Nakajima A; Idilman R; Gumussoy M; Oz DK; Erden A; Loomba R
Aliment Pharmacol Ther; 2023 Nov; 58(9):856-865. PubMed ID: 37694993
[TBL] [Abstract][Full Text] [Related]
26. Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF).
Noureddin M; Truong E; Mayo R; Martínez-Arranz I; Mincholé I; Banales JM; Arrese M; Cusi K; Arias-Loste MT; Bruha R; Romero-Gómez M; Iruzubieta P; Aller R; Ampuero J; Calleja JL; Ibañez-Samaniego L; Aspichueta P; Martín-Duce A; Kushner T; Ortiz P; Harrison SA; Anstee QM; Crespo J; Mato JM; Sanyal AJ
Hepatology; 2024 Jan; 79(1):135-148. PubMed ID: 37505221
[TBL] [Abstract][Full Text] [Related]
27. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
; ; ;
J Hepatol; 2024 Jun; ():. PubMed ID: 38851997
[TBL] [Abstract][Full Text] [Related]
28. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
; ;
Obes Facts; 2024 Jun; ():1-70. PubMed ID: 38852583
[TBL] [Abstract][Full Text] [Related]
29. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
[TBL] [Abstract][Full Text] [Related]
30. Validation of magnetic resonance elastography plus fibrosis-4 for significant fibrosis in nonalcoholic fatty liver disease.
Inada K; Tamaki N; Kurosaki M; Kirino S; Yamashita K; Hayakawa Y; Higuchi M; Takaura K; Kaneko S; Maeyashiki C; Yasui Y; Tsuchiya K; Nakanishi H; Izumi N
J Gastroenterol Hepatol; 2022 Sep; 37(9):1726-1731. PubMed ID: 35587726
[TBL] [Abstract][Full Text] [Related]
31. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis.
Jung J; Loomba RR; Imajo K; Madamba E; Gandhi S; Bettencourt R; Singh S; Hernandez C; Valasek MA; Behling C; Richards L; Fowler K; Sirlin CB; Nakajima A; Loomba R
Gut; 2021 Oct; 70(10):1946-1953. PubMed ID: 33214165
[TBL] [Abstract][Full Text] [Related]
32. Fibrotic NASH in Individuals with Obesity: a Cross-sectional Analysis of the Prevalence of this Significant Milestone of Disease Progression and Accuracy of a Non-invasive Marker for its Screening.
de Souza Echeverria L; Mounzer DLS; Gestic MA; Utrini MP; Chaim FDM; Callejas-Neto F; Chaim EA; Cazzo E
Obes Surg; 2024 Feb; 34(2):389-395. PubMed ID: 38110785
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.
Selvaraj EA; Mózes FE; Jayaswal ANA; Zafarmand MH; Vali Y; Lee JA; Levick CK; Young LAJ; Palaniyappan N; Liu CH; Aithal GP; Romero-Gómez M; Brosnan MJ; Tuthill TA; Anstee QM; Neubauer S; Harrison SA; Bossuyt PM; Pavlides M;
J Hepatol; 2021 Oct; 75(4):770-785. PubMed ID: 33991635
[TBL] [Abstract][Full Text] [Related]
34. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
35. Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease.
Gao F; Huang JF; Zheng KI; Pan XY; Ma HL; Liu WY; Byrne CD; Targher G; Li YY; Chen YP; Chan WK; Zheng MH
J Gastroenterol Hepatol; 2020 Oct; 35(10):1804-1812. PubMed ID: 32246876
[TBL] [Abstract][Full Text] [Related]
36. Fibroscan-AST (FAST) score and other non-invasive tests for the diagnosis of fibrotic non-alcoholic steatohepatitis.
Chan WL; Chandra Kumar CV; Chan WK
Hepatobiliary Surg Nutr; 2023 Oct; 12(5):763-767. PubMed ID: 37886205
[No Abstract] [Full Text] [Related]
37. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.
Sanyal AJ; Foucquier J; Younossi ZM; Harrison SA; Newsome PN; Chan WK; Yilmaz Y; De Ledinghen V; Costentin C; Zheng MH; Wai-Sun Wong V; Elkhashab M; Huss RS; Myers RP; Roux M; Labourdette A; Destro M; Fournier-Poizat C; Miette V; Sandrin L; Boursier J
J Hepatol; 2023 Feb; 78(2):247-259. PubMed ID: 36375686
[TBL] [Abstract][Full Text] [Related]
38. Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria.
Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Jang JY; Park SY; Lee HW; Lee CK; Kim SU
Front Med (Lausanne); 2022; 9():869190. PubMed ID: 35492369
[TBL] [Abstract][Full Text] [Related]
39. Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD).
Duseja A; Singh SP; De A; Madan K; Rao PN; Shukla A; Choudhuri G; Saigal S; Shalimar ; Arora A; Anand AC; Das A; Kumar A; Eapen CE; Devadas K; Shenoy KT; Panigrahi M; Wadhawan M; Rathi M; Kumar M; Choudhary NS; Saraf N; Nath P; Kar S; Alam S; Shah S; Nijhawan S; Acharya SK; Aggarwal V; Saraswat VA; Chawla YK
J Clin Exp Hepatol; 2023; 13(2):273-302. PubMed ID: 36950481
[TBL] [Abstract][Full Text] [Related]
40. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease.
Puchakayala BK; Verma S; Kanwar P; Hart J; Sanivarapu RR; Mohanty SR
World J Hepatol; 2015 Nov; 7(25):2610-8. PubMed ID: 26557954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
